CORE--PHARMACOLOGY

核心--药理学

• 批准号: 6989940
• 负责人: MATTHEW M AMES
• 金额: $ 16.55万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-15 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6989940
• 关键词: antineoplastics; biomedical facility; drug adverse effect; neoplasm /cancer; oncology; pharmacy

The Mayo Clinic Cancer Center Pharmacy Shared Resource provides comprehensive pharmacy services in support of approximately 200 active cancer clinical trials across the 3 campuses of Mayo Rochester, Mayo Jacksonville, and Mayo Sccttsdale. The Pharmacy Shared Resource provides procurement, storage, and accountability of investigational agents. In addition, admixture of cytotoxic chemotherapy, growth factors, immunomodulatory agents, antiemetics, and supportive care medication is provided. The services of the Pharmacy Shared Resource are essential for protocol development, protocol initiation, and patient treatment on clinical trials throughout the Mayo Clinic Cancer Center. Special expertise with both investigational and commercially available cancer therapeutic agents resides in the Cancer Center Pharmacy Shared Resource, ensuring a uniformly high standard of safe and accurate treatment for all Mayo Clinic cancer patients. The utilization of the Pharmacy Shared Resource has increased over the past five years as noted by the number of patients treated on clinic trials. In 2002 the number of patients treated on clinical trials at the Mayo Clinic Cancer Center that utilized the Pharmacy Shared Resource was 1549, compared to 573 in 1997. This increase was due to the steady increase in patient accrual and the integration of Mayo Clinic Jacksonville and Mayo Clinic Scottsdale. The increased utilization of the Pharmacy Shared Resource is also demonstrated by an increased number of Mayo Clinic Cancer Center members utilizing the services of the Pharmacy core as well as the increased number of protocols in development. The main mission of the Pharmacy Shared Resource is to provide protocol development and review, investigational drug accountability, and chemotherapy admixture and dispensing services. The implementation of policies and procedures consistent with American Society of Health Systems Pharmacy guidelines and Joint Commission on Accreditation of Healthcare Organizations recommendations at each site ensures regulatory compliance and provides a uniform level of safe, high quality care to all Mayo Clinic Cancer Center patients.

梅奥诊所癌症中心药房共享资源提供综合药房 服务支持梅奥罗切斯特、梅奥杰克逊维尔和梅奥斯克茨代尔 3 个校区的约 200 项活跃的癌症临床试验。药房共享资源提供研究药物的采购、存储和问责。此外，还提供细胞毒性化疗、生长因子、免疫调节剂、止吐剂和支持治疗药物的混合物。药房共享资源的服务对于梅奥诊所癌症中心临床试验的方案制定、方案启动和患者治疗至关重要。癌症中心药房共享资源拥有研究性和市售癌症治疗药物的特殊专业知识，确保为所有梅奥患者提供统一的高标准安全和准确的治疗 临床癌症患者。 从临床试验中接受治疗的患者数量可以看出，药房共享资源的利用率在过去五年中有所增加。 2002 年，在 Mayo Clinic 癌症中心利用药房共享资源接受临床试验治疗的患者人数为 1549 人，而 1997 年为 573 人。这一增长是由于患者数量的稳步增长以及 Mayo Clinic 杰克逊维尔和梅奥诊所癌症中心的整合。斯科茨代尔梅奥诊所。药房共享资源利用率的提高还体现在越来越多的梅奥诊所癌症中心成员利用药房核心服务以及正在开发的方案数量增加。 药房共享资源的主要任务是提供方案制定和审查、研究药物责任以及化疗混合和配药服务。在每个地点实施符合美国卫生系统协会药房指南和医疗保健组织认证联合委员会建议的政策和程序，确保遵守法规，并为所有梅奥诊所癌症中心患者提供统一水平的安全、高质量护理。